- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CGRP Inhibitor Erenumab Gains EU Approval for Migraine Prevention
The once-monthly self-injected calcitonin gene-related peptide (CGRP) inhibitor is now approved in the European Union, Switzerland, the United States, and Australia.
Novartis and Amgen’s first-of-its-kind calcitonin gene-related peptide (CGRP) inhibitor ereunmab (Aimovig) has gained its fourth approval—this time in the European Union.
The European Commission green-lighted the migraine prevention treatment for adults who experience 4 or more migraine days per month and have previously failed on 2 to 4 previous treatments. Users can self-administer the autoinjector pen every 4 weeks. The CGRP inhibitor is now approved in the European Union, Switzerland, the United States, and Australia.
“Migraine matters. It is a painful, highly disruptive neurological disease that affects all aspects of life, from going to work to spending time with family and friends,” said Patrick Little, president, European Migraine and Headache Alliance, in a statement. “A treatment specifically designed for migraine prevention is a much-welcomed innovation and could transform lives of patients for whom current therapies do not work or are not well tolerated.”
According to Novartis, patients administered erenumab in clinical trials have reported consistent and sustained migraine prevention, with many experiencing a 50% or greater reduction in monthly migraine days. Safety and tolerability were comparable with that of placebo. An interim analysis from a 5-year open label extension in episodic migraine demonstrated that more than a quarter (26%) of patients taking 70 mg of erenumab were completely migraine-free.
“Erenumab heralds a new era in clinical practice, bringing both a targeted mechanism for prevention and a deep understanding of migraine, which we never had before,” said Petere Goadsby, MD, PhD, FRCP, director, NIHR-Wellcome Trust King’s Clinical Research Facility and professor of neurology at King’s College London, in a statement.
The EU approval comes just a few months after the FDA’s approval of erenumab for migraine prevention, making it the first CGRP inhibitor to be approved in the US. The approval followed positive results of the LIBERTY trial, which assessed the treatment in patients with episodic migraine. Patients taking erenumab had nearly 3-fold higher odds of having their migraine days reduced by at least 50%.
The list price totals $575 a month in the United States, or $6900 annually, which comes cheaper than previously expected. Analysts predicted the treatment would amount to $10,000 a year.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen
